What is rolapitant, and what patents cover it?
Rolapitant is an NK1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). The “rolapitant spiro patent” phrasing usually refers to patents that claim rolapitant and/or its related chemical structures, including variants described using “spiro” (spirocyclic) chemistry.
I don’t have the specific patent number(s) or jurisdiction in your prompt, so I can’t identify the exact “rolapitant spiro” patent or its claim scope from the provided information.
What does “spiro” mean in a rolapitant patent context?
In patents, “spiro” typically describes a spirocyclic ring system in the compound structure. Patent documents may include such language in the chemical description or in the claims that define the covered molecules (for example, a specific spirocyclic scaffold tied to activity at NK1).
If you share the patent number, assignee, or a link, I can explain:
- what the “spiro” chemical wording means in the claim,
- whether it covers rolapitant itself or a specific analog/derivative,
- and which part of the molecule is doing the legal “claim work.”
When does the rolapitant patent expire?
Patent expiration depends on the country/region and the specific patent family (and can be extended by patent-term adjustment, pediatric extensions, etc.). Without the exact patent number and jurisdiction, I can’t provide an accurate expiry timeline.
If you tell me the country (e.g., US, EP, UK, JP, CN, IN) or provide the patent publication number (like US20xx/xxxxxxx or EPxxxxxxx), I can map:
- the likely earliest priority date,
- the scheduled expiration date,
- and whether any extensions are known from the public record.
How do “spiro” rolapitant patents affect generic or biosimilar entry?
If a “spiro” patent covers a core chemical structure in the marketed rolapitant drug substance, it can delay generic launches while that claim remains in force. If the patent covers only narrower analogs or an intermediate, it may have less blocking power for a generic that uses a different structure or a non-infringing route.
To evaluate this, I need either:
- the patent publication number, or
- the key claim language (especially the spirocyclic definition).
Can you share the exact patent you mean?
Reply with any one of the following and I’ll give a targeted, patent-specific answer:
1) the patent number or publication number (US/EP/etc.),
2) the assignee/applicant name, or
3) a link to the patent document,
4) the exact wording around “spiro” from the claims.
Sources
None provided in your prompt.